ALVR (AlloVir) GF Value Rank : 0 (As of Apr. 16, 2025)

View and export this data going back to 2020. Start your Free Trial

What is AlloVir GF Value Rank?

AlloVir has the GF Value Rank of 0.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

AlloVir GF Value Rank Related Terms

Thank you for viewing the detailed overview of AlloVir's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AlloVir Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AlloVir Inc (NAS:ALVR) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1661 Massachusetts Avenue, PO Box 44, Lexington, MA, USA, 02420

Website

https://www.allovir.com

AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy. (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses. (3) ALVR107, an allogeneic, off-the-shelf VST therapy candidate designed to target hepatitis B (HBV).

Executives

Vikas Sinha	director, 10 percent owner, officer: See Remarks	C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Edward Miller	officer: General Counsel	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Brett R Hagen	officer: Chief Accounting Officer	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Diana Brainard	director	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Cintia Piccina	officer: Chief Commercial Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Derek N. Adams	director	ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451
Van Beek Jeroen B	officer: Chief Commercial Officer	C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Ercem Atillasoy	officer: See Remarks	C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
David Hallal	director, 10 percent owner, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
F2 - Tpo Investments Llc	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018
F2 Bioscience Av 2022 Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Capital I 2020 F2	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
F2 Mc, Llc	director, 10 percent owner	8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018
Globeways Holdings Ii Ltd	director, 10 percent owner	C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018